alexa Mycoplasma pneumoniae Infection | Finland| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Relevant Topics

Mycoplasma Pneumoniae Infection

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Mycoplasma pneumoniae Infection

    Mycoplasma pneumonia is an infection of the lungs by the bacteria Mycoplasma pneumoniae (M. pneumoniae). This type of pneumonia is also called atypical pneumonia because the symptoms are different from those of pneumonia due to other common bacteria.People who live or work in crowded areas such as schools and homeless shelters have a high chance of getting this condition. But many people who get sick with it have no known risk factors.

  • Mycoplasma pneumoniae Infection

    The number of cases of Mycoplasma pneumoniae infection detected by laboratory-based surveillance increased in Finland in late 2010. During 2011, the number of cases was four times higher than during the previous epidemic in 2005. The 2011 epidemic affected mostly school-age children. The number of cases dropped between April and July 2011 and then started to increase again in September 2011. The number of cases rose from 1,948 (36.2 per 100,000 population) in 2010 to 7,772 (145 per 100,000 population) in 2011. 

  • Mycoplasma pneumoniae Infection

    MP is a bacterial infection the first line of treatment is antibiotics. Antibiotics must differ for children to avoid any potentially dangerous side effects. Macrolides, the first choice of antibiotics for children, include:erythromycin, clarithromycin, roxithromycin, azithromycin. Antibiotics prescribed for adults include: doxycycline, tetracycline, quinolones, Corticosteroids. Not all people respond to antibiotic treatment. Treatment for those who are unresponsive to antibiotics or complications of illness include corticosteroids.

  • Mycoplasma pneumoniae Infection

    Future studies, with new molecular techniques to better detect infections due to the wide range of pathogens, will broaden our understanding of the cause of pneumonia and may highlight which pathogens should be the targets for new vaccines. Despite the lack of data, mainly for the developing regions of the world, morbidity and mortality estimates and the main risk factors presented in this review could contribute to an understanding of the burden of acute lower respiratory infections.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings